Treats hypertension. ANDA 202463, held by Actavis Elizabeth. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 202463 (Diltiazem Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Dec 7, 2012, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 7, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diltiazem Hydrochloride360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Sep 11, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 11, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 11, 2025 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 7, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters